05:05 PM EDT, 08/25/2025 (MT Newswires) -- Serina Therapeutics ( SER ) said Monday that written feedback from the US Food and Drug Administration, following a recent Type B meeting, supports advancing SER-252 in a registrational trial program for advanced Parkinson's disease under the 505(b)(2) new drug application pathway.

The investigational new drug application filing is slated for Q4 and US enrollment is expected to begin in Q1, the company said.

In parallel, Serina expects to start dosing patients in Australia in Q4 as part of a global registrational program.

The company's shares rose 28% in after-hours trading.